Novartis International AG announced Russian regulatory approval for Gilenya(R), a once-daily oral multiple sclerosis therapy and first in a new class processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
- Russia is first country to approve Gilenya for the treatment of relapsing remitting MS, the most common form of the disease
- Gilenya is the first disease-modifying treatment in a new drug class and offers significant efficacy with a well-characterized safety tolerability profile
- Action from the US Food and Drug Administration (FDA) on Gilenya is expected in September 2010; other submissions under review worldwide... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309